title: Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease.
abstract: Posaconazole is a triazole antifungal in development for the treatment of invasive fungal infections. The authors evaluated the pharmacokinetics and safety of posaconazole in healthy subjects and in those with mild (CL(CR) = 50-80 mL/min), moderate (CL(CR) = 20-49 mL/min), and severe chronic renal disease (CL(CR) <20 mL/min; receiving outpatient hemodialysis) (n = 6/group). Subjects received one 400-mg dose of posaconazole oral suspension with a standardized high-fat breakfast. For hemodialysis-dependent subjects, this dose was given on a nonhemodialysis day, and a second 400-mg dose was given 6 hours before hemodialysis. Blood samples were collected before dose and up to 120 hours postdose. For hemodialysis-dependent subjects following the second dose, additional samples (predialyzed and postdialyzed) were collected before, during, and after dialysis. There was no correlation between posaconazole pharmacokinetics and mild to moderate renal disease; the slopes of the linear regressions for creatinine clearance versus posaconazole AUC, C(max), CL/F, and t1/2 values were not significantly different from zero (P > .130). Mean CL/F values before and during hemodialysis were comparable. Furthermore, the difference in the predialyzed and postdialyzed posaconazole concentrations was only approximately 3%, supporting that posaconazole was not removed by hemodialysis. Protein binding was similar in all groups (approximately 98%) and was unaffected by hemodialysis. Posaconazole was generally well tolerated. One patient had elevated liver function test results that were not present at baseline and were thought to be possibly related to posaconazole. Results of this single-dose study indicate that dosage adjustments for patients with varying degrees of renal disease are not required.
authors.affiliation: Schering-Plough Research Institute, K-15-4-4465, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.
authors.forename: R
authors.initials: R
authors.lastname: Courtney
authors.forename: A
authors.initials: A
authors.lastname: Sansone
authors.forename: W
authors.initials: W
authors.lastname: Smith
authors.forename: T
authors.initials: T
authors.lastname: Marbury
authors.forename: P
authors.initials: P
authors.lastname: Statkevich
authors.forename: M
authors.initials: M
authors.lastname: Martinho
authors.forename: M
authors.initials: M
authors.lastname: Laughlin
authors.forename: S
authors.initials: S
authors.lastname: Swan
mesh_terms: D000284:Administration, Oral; D000410:Alanine Transaminase / Q000187:drug effects / Q000378:metabolism; D019540:Area Under Curve; D001219:Aspartate Aminotransferases / Q000187:drug effects / Q000378:metabolism; D001682:Biological Availability; D003404:Creatinine / Q000378:metabolism; D004041:Dietary Fats / Q000008:administration & dosage / Q000493:pharmacokinetics; D004334:Drug Administration Schedule; D004435:Eating; D005260:Female; D006207:Half-Life; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000453:epidemiology; D008111:Liver Function Tests / Q000009:adverse effects; D008297:Male; D008657:Metabolic Clearance Rate / Q000187:drug effects / Q000502:physiology; D008875:Middle Aged; D011485:Protein Binding / Q000187:drug effects; D006435:Renal Dialysis / Q000379:methods; D013535:Suspensions; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage / Q000378:metabolism / Q000493:pharmacokinetics*
chemical_list: D004041:Dietary Fats; D013535:Suspensions; D014230:Triazoles; C101425:posaconazole; D003404:Creatinine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase